Polypeptide targeting novel coronavirus COVID-19 and application of polypeptide
The invention provides a polypeptide targeting novel coronavirus COVID-19 and application of the polypeptide. The polypeptide comprises an amino acid sequence shown as SEQ ID NO: 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugation connection carbon chains to the N end and/or the C end of SEQ ID NO: 1-28 and has the activity oftargeting coronavirus COVID-19. The polypeptide library is synthesized by adopting a combined chemical method of one bead and one compound (one-by-one-complex, OBOC), so that the polypeptide libraryis obtained. By utilizing the polypeptide library and the S protein on the surface of the novel coronavirus, the screened polypeptide has strong binding capacity with the S protein of the coronavirusCOVID-19, and a basis is provided for research and development of novel coronavirus detection reagents and treatment drugs..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Europäisches Patentamt - (2020) vom: 07. Aug. Zur Gesamtaufnahme - year:2020 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
WANG HAO [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2020-08-07, Last update posted on www.tib.eu: 2022-04-09, Last updated: 2023-02-09 |
|---|
| Patentnummer: |
CN111499692 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA005981883 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA005981883 | ||
| 003 | DE-627 | ||
| 005 | 20230504120126.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210531s2020 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA005981883 | ||
| 035 | |a (EPA)CN111499692 | ||
| 035 | |a (EPA)71873805 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a WANG HAO |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Polypeptide targeting novel coronavirus COVID-19 and application of polypeptide |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2020-08-07, Last update posted on www.tib.eu: 2022-04-09, Last updated: 2023-02-09 | ||
| 520 | |a The invention provides a polypeptide targeting novel coronavirus COVID-19 and application of the polypeptide. The polypeptide comprises an amino acid sequence shown as SEQ ID NO: 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugation connection carbon chains to the N end and/or the C end of SEQ ID NO: 1-28 and has the activity oftargeting coronavirus COVID-19. The polypeptide library is synthesized by adopting a combined chemical method of one bead and one compound (one-by-one-complex, OBOC), so that the polypeptide libraryis obtained. By utilizing the polypeptide library and the S protein on the surface of the novel coronavirus, the screened polypeptide has strong binding capacity with the S protein of the coronavirusCOVID-19, and a basis is provided for research and development of novel coronavirus detection reagents and treatment drugs. | ||
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
| 650 | 4 | |a G01N: Investigating or analysing materials by determining their chemical or physical properties (measuring or testing processes other than immunoassay, involving enzymes or microorganisms c12m, c12q) | |
| 650 | 4 | |a tec | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a WANG LEI |4 aut | |
| 700 | 0 | |a YANG PEIPEI |4 aut | |
| 700 | 0 | |a AN HONGWEI |4 aut | |
| 700 | 0 | |a ZHAO YULIANG |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2020) vom: 07. Aug. |
| 773 | 1 | 8 | |g year:2020 |g day:07 |g month:08 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/71873805/publication/CN111499692A1?q=CN111499692 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | u | w | |j 2020 |b 07 |c 08 |
| 951 | |a AR | ||
| 952 | |j 2020 |b 07 |c 08 | ||